- Home
- AIRS vs GLSI Comparison
AIRS vs GLSI Comparison
Compare AIRS & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- GLSI
- Stock Information
- Founded
- AIRS 2012
- GLSI 2006
- Country
- AIRS United States
- GLSI United States
- Employees
- AIRS N/A
- GLSI N/A
- Industry
- AIRS Medical/Nursing Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- GLSI Health Care
- Exchange
- AIRS Nasdaq
- GLSI Nasdaq
- Market Cap
- AIRS 166.3M
- GLSI 134.6M
- IPO Year
- AIRS 2021
- GLSI 2020
- Fundamental
- Price
- AIRS $6.45
- GLSI $11.48
- Analyst Decision
- AIRS Hold
- GLSI Strong Buy
- Analyst Count
- AIRS 3
- GLSI 1
- Target Price
- AIRS $3.75
- GLSI $39.00
- AVG Volume (30 Days)
- AIRS 724.6K
- GLSI 43.7K
- Earning Date
- AIRS 08-01-2025
- GLSI 08-14-2025
- Dividend Yield
- AIRS N/A
- GLSI N/A
- EPS Growth
- AIRS N/A
- GLSI N/A
- EPS
- AIRS N/A
- GLSI N/A
- Revenue
- AIRS $165,109,000.00
- GLSI N/A
- Revenue This Year
- AIRS N/A
- GLSI N/A
- Revenue Next Year
- AIRS $5.14
- GLSI N/A
- P/E Ratio
- AIRS N/A
- GLSI N/A
- Revenue Growth
- AIRS N/A
- GLSI N/A
- 52 Week Low
- AIRS $1.53
- GLSI $8.06
- 52 Week High
- AIRS $9.20
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- AIRS 53.51
- GLSI 48.08
- Support Level
- AIRS $5.80
- GLSI $11.35
- Resistance Level
- AIRS $6.90
- GLSI $12.07
- Average True Range (ATR)
- AIRS 0.53
- GLSI 0.57
- MACD
- AIRS -0.03
- GLSI -0.12
- Stochastic Oscillator
- AIRS 38.92
- GLSI 8.78
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.